Where does Oncotherapy Science, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Oncotherapy Science, Inc. ranks #5,176 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Oncotherapy Science, Inc. hold?

Oncotherapy Science, Inc. holds 67 US utility patents granted between 2015 and 2025, spanning 16 technology areas.

What is Oncotherapy Science, Inc.'s Innovation Score?

Oncotherapy Science, Inc. has an Innovation Score of 37.1 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Oncotherapy Science, Inc. focus on?

Oncotherapy Science, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 62 patents, ranking #331 of 7,163 assignees active in that subclass. Grants appear in 16 CPC subclasses total.

Is Oncotherapy Science, Inc.'s patent grant rate increasing or decreasing?

Oncotherapy Science, Inc.'s recent grant velocity is -68% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Oncotherapy Science, Inc.'s patents?

Oncotherapy Science, Inc.'s patents average 10.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Oncotherapy Science, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Oncotherapy Science, Inc.

USPTO PatentsView assignee record - 67 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oncotherapy ranks #5,176 of 49,997 tracked US assignees by granted-patent volume, with 67 patents across 16 technology areas.

#5,176
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.1/100): 10.1
avg claims per patent: -68%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5176 · Foreign Corporation #5,176 · 67 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 67 grants
UPPER-Q #5,176/49,997
PHOTO-FINISH Magna Powertrain
CPC-FOCUS A61K · 16 areas
INNOV-THIN 37.1/100
CLAIMS-PAR 10.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -68% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Magna Powertrain, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oncotherapy’s 37.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.6 pts (39%) Velocity 2.4 pts (6%) Breadth 14.1 pts (38%) Claim depth 6.0 pts (16%)

Qualcomm Incorporated · highest

85
Miltenyi Biotec · near

37
Modernsolid Industrial · near

37
Oncotherapy Science · this assignee

37
TYR Tactical · near

37
LG Fuel Cell Systems · near

37
3D Lighting… · lowest

7

What this shows Oncotherapy's Innovation Score is 37.1/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oncotherapy?

Each dot is one of Oncotherapy’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncotherapy’s own 10.1 claims/patent is at or below the 17.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Oncotherapy vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oncotherapy's grants concentrate

Oncotherapy Science, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 92.5% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (23 grants) versus a trough of 2 in 2022. By volume, Oncotherapy sits between Magna Powertrain, Inc. and Shengyi Technology Co., Ltd..

Oncotherapy's three-year grant acceleration

Oncotherapy Science, Inc. shows 5 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Magna Powertrain

67
Moen Incorporated

67
NCS Multistage

67
National Universi…

67
Optos

67
Preh

67
Proterra

67
Shengyi Technology

67
Oncotherapy Scien… ◀

67

What this shows Oncotherapy holds 67 patents at rank #5,176, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Oncotherapy

By rank, the assignees closest to #5,176 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Oncotherapy's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Oncotherapy, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Oncotherapy ranks #331 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

Modernsolid Industrial Co., Ltd. 37 Miltenyi Biotec, Inc. 37 TYR Tactical, LLC 37 LG Fuel Cell Systems Inc. 37

Similar claim depth

Nearest assignees by average claims per patent (10.1 here).

Guangdong Midea Kitchen Appliances Manufacturing Co., Ltd. 10.1 avg Cal-comp Electronics & Communications Company Limited 10.1 avg Mitsubishi Electric Corporation 10.1 avg Bridgeport Fittings, LLC 10.1 avg

Oncotherapy's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Oncotherapy Science, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	23	34.3%
2016	9	13.4%
2017	12	17.9%
2018	3	4.5%
2019	3	4.5%
2020	8	11.9%
2021	3	4.5%
2022	2	3.0%
2023	3	4.5%
2025partial year	1	1.5%

Which technologies does Oncotherapy Science, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 62

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 61

C07K - Peptides 60

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 41

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 24

C12Y - Enzymes 14

C07D - Heterocyclic Compounds 6

Y02A - Technologies FOR Adaptation TO Climate Change 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 1

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 15 of 16 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Oncotherapy Science, Inc.'s patent record in context - here's where to go next.

Oncotherapy Science, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 92.5% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #5,176 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Oncotherapy Science, Inc. against Magna Powertrain, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.